Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02163057 · ClinicalTrials.gov registry record · Phase 1
Study of HPV Specific Immunotherapy in Participants With HPV Associated Head and Neck Squamous Cell Carcinoma
A Phase 1 study, sponsored by Inovio Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 22
- Enrollment target
NCT02163057 is a Phase 1 study that has completed, run by Inovio Pharmaceuticals. The registered enrollment target is 22 participants.
The verdict
NCT02163057, a Phase 1 study, has completed, sponsored by Inovio Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 22 participants
- Enrollment target
Study Summary
This is a Phase I/IIa, open-label study to evaluate the safety, tolerability, and immunogenicity of INO-3112 DNA vaccine delivered by electroporation (EP) to participants with human papilloma virus (HPV) associated head and neck squamous cell cancer (HNSCC).
Interventions
- BIOLOGICAL INO-3112
- DEVICE CELLECTRA™-5P
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 22 participants |
| Start Date | 2014-08-13 |
| Est. Completion | 2017-01-23 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02163057
The ClinicalTrials.gov registry entry for NCT02163057 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 22 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Inovio Pharmaceuticals, which has 28 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which INO-3112 is the first listed.
NCT02163057 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02163057 about?
NCT02163057 is a clinical study titled "Study of HPV Specific Immunotherapy in Participants With HPV Associated Head and Neck Squamous Cell Carcinoma". This is a Phase I/IIa, open-label study to evaluate the safety, tolerability, and immunogenicity of INO-3112 DNA vaccine delivered by electroporation (EP) to participants with human papilloma virus (HPV) associated head and neck squamous cell cancer (HNSCC).
What is the current status of trial NCT02163057?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 22 participants. The study started on 2014-08-13. Estimated completion is 2017-01-23.
What interventions are being tested in trial NCT02163057?
The interventions under investigation include: INO-3112 (BIOLOGICAL), CELLECTRA™-5P (DEVICE).
Who is sponsoring clinical trial NCT02163057?
This trial is sponsored by Inovio Pharmaceuticals, which has 28 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.